Expression of annexin A5 is associated with higher tumor stage and poor prognosis in colorectal adenocarcinomas

Journal of Clinical Gastroenterology

Volumn 43, Issue 9, 2009, Pages 831-837

  Xue, Geng ^a   Hao, Li Qiang ^b   Ding, Fei Xiang ^a   Mei, Qian ^a   Huang, Jing Jing ^a   Fu, Chuan Gang ^b   Yan, Hong Li ^a   Sun, Shu Han ^a  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

^b SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Annexin A5; Clinical outcome; Colorectal cancer; Tumor stage

Indexed keywords

LIPOCORTIN 5; MESSENGER RNA;

ADULT; AGED; ARTICLE; CANCER MORTALITY; CANCER RECURRENCE; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; COLORECTAL ADENOCARCINOMA; COLORECTAL CANCER; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER METASTASIS; LYMPH NODE METASTASIS; MALE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROBABILITY; PROGNOSIS; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UPREGULATION;

ADENOCARCINOMA; AGED; ANNEXIN A5; COLORECTAL NEOPLASMS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIERS ESTIMATE; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROPORTIONAL HAZARDS MODELS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RISK ASSESSMENT; RISK FACTORS; RNA, MESSENGER; TIME FACTORS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; UP-REGULATION;

EID: 70349668512     PISSN: 01920790     EISSN: None     Source Type: Journal    
DOI: 10.1097/MCG.0b013e31819cc731     Document Type: Article

References (26)

1. Watson AJ. An overview of apoptosis and the prevention of colorectal cancer. Crit Rev Oncol Hematol. 2006;57:107-121. (Pubitemid 43139699)
2. Kahi CJ, Rex DK, Imperiale TF. Screening, surveillance, and primary prevention for colorectal cancer: a review of the recent literature. Gastroenterology. 2008;135:380-399.
3. Wilkinson N, Scott-Conner CE. Surgical therapy for colorectal adenocarcinoma. Gastroenterol Clin North Am. 2008;37: 253-267, ix.
4. Wolpin BM, Mayer RJ. Systemic treatment of colorectal cancer. Gastroenterology. 2008;134:1296-1310.
5. Kasztelan-Szczerbiñska B, Cichoz-Lach H, S"omka M. Colorectal cancer as a health care problem: evaluation of the current diagnostic options. Pol Arch Med Wewn. 2008;118:224-227.
6. Walsh JM, Terdiman JP. Colorectal cancer screening: scientific review. JAMA. 2003;289:1288-1296. (Pubitemid 37432910)
7. Boursi B, Arber N. Current and future clinical strategies in colon cancer prevention and the emerging role of chemoprevention. Curr Pharm Des. 2007;13:2274-2282. (Pubitemid 47317035)
8. Denlinger CS, Cohen SJ. Progress in the development of prognostic and predictive markers for gastrointestinal malignancies. Curr Treat Options Oncol. 2007;8:339-351.
9. Zlobec I, Lugli A. Prognostic and predictive factors in colorectal cancer. J Clin Pathol. 2008;61:561-569. (Pubitemid 351688621)
10. Hayes MJ, Moss SE. Annexins and disease. Biochem Biophys Res Commun. 2004;322:1166-1170.
11. Gerke V, Moss SE. Annexins: from structure to function. Physiol Rev. 2002;82:331-371.
12. Hawkins TE, Merrifield CJ, Moss SE. Calcium signaling and annexins. Cell Biochem Biophys. 2000;33:275-296.
13. Rescher U, Gerke V. Annexins - unique membrane binding proteins with diverse functions. J Cell Sci. 2004;117(Pt 13): 2631-2639. (Pubitemid 38997247)
14. Futter CE, White IJ. Annexins and endocytosis. Traffic. 2007; 8:951-958.
15. 2+-binding site in the mechanism of inhibition. J Biol Chem. 1997;272:10474-10482.
16. Karube A, Shidara Y, Hayasaka K, et al. Suppression of calphobindin I (CPB I) production in carcinoma of uterine cervix and endometrium. Gynecol Oncol. 1995;58:295-300.
17. Mulla A, Christian HC, Solito E, et al. Expression, subcellular localization and phosphorylation status of annexins 1 and 5 in human pituitary adenomas and a growth hormone-secreting carcinoma. Clin Endocrinol (Oxf). 2004;60:107-119. (Pubitemid 38183506)
18. Liu W, Saint DA. Validation of a quantitative method for real time PCR kinetics. Biochem Biophys Res Commun. 2002;294: 347-353. (Pubitemid 34694101)
19. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2[-Delta Delta C (T)] Method. Methods. 2001;25:402-408. (Pubitemid 34164012)
20. Guzmán-Aránguez A, Olmo N, Turnay J, et al. Differentiation of human colon adenocarcinoma cells alters the expression and intracellular localization of annexins A1, A2, and A5. J Cell Biochem. 2005;94:178-193. (Pubitemid 41420335)
21. Boersma HH, Kietselaer BL, Stolk LM, et al. Past, present, and future of annexin A5: from protein discovery to clinical applications. J Nucl Med. 2005;46:2035-2050.
22. Kenis H, Hofstra L, Reutelingsperger CP. Annexin A5: shifting from a diagnostic towards a therapeutic realm. Cell Mol Life Sci. 2007;64:285928- 285962. (Pubitemid 351152249)
23. Monceau V, Belikova Y, Kratassiouk G, et al. Externalization of endogenous annexin A5 participates in apoptosis of rat cardiomyocytes. Cardiovasc Res. 2004;64:496-506. (Pubitemid 39505428)
24. Cardó-Vila M, Arap W, Pasqualini R. Alpha v beta 5 integrin-dependent programmed cell death triggered by a peptide mimic of annexin V. Mol Cell. 2003;11:1151-1162. (Pubitemid 36645136)
25. Kheifets V, Bright R, Inagaki K, et al. Protein kinase C delta (deltaPKC)-annexin V interaction: a required step in deltaPKC translocation and function. J Biol Chem. 2006;281: 23218-23226. (Pubitemid 44242352)
26. Yamaguchi T, Matsuda K, Sagiya Y, et al. p53R2-dependent pathway for DNA synthesis in a p53-regulated cell cycle checkpoint. Cancer Res. 2001;61:8256-8262. (Pubitemid 33091620)